The effects of weight on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules

被引：0
|
作者：
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
机构：
来源：
MOVEMENT DISORDERS | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
410
引用
收藏
页码：S146 / S147
页数：2
相关论文
共 50 条
  • [31] Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®)
    Hsu, Ann
    Yao, Hsuan-Ming
    Gupta, Suneel
    Modi, Nishit B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09): : 995 - 1003
  • [32] Comparison of IPX066, a Carbidopa-Levodopa Extended Release Formulation with CD-LD IR plus Entacapone in Patients with Advanced Parkinson's Disease
    Stocchi, Fabrizio
    Hsu, Ann
    Khanna, Sarita
    Ellenbogen, Aaron
    Mahler, Andreas
    Liang, Grace
    Dillmann, U.
    Rubens, Robert
    Kell, Sherron
    Gupta, Suneel
    ANNALS OF NEUROLOGY, 2013, 74 : S42 - S42
  • [33] Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
    Modi, Nishit B.
    Mittur, Aravind
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    CLINICAL NEUROPHARMACOLOGY, 2019, 42 (01) : 4 - 8
  • [34] Improvements in activities of daily living and quality of life measures in Hoehn & Yahr subgroups of advanced Parkinson's disease patients following treatment with IPX066, extended-release carbidopa-levodopa
    Dhall, Rohit
    Gil, Ramon
    Lindemulder, Elizabeth
    Rubens, Robert
    Gupta, Suneel
    NEUROLOGY, 2017, 88
  • [35] Comparative efficacy and safety of a novel carbidopa-levodopa product (IPX066) and Sinemet in advanced Parkinson's disease
    Ellenbogen, A.
    Hauser, R.
    Omidvar, O.
    Hsu, A.
    O'Connell, M.
    Kell, S.
    Gupta, S.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S126 - S126
  • [36] Dose conversion to IPX066 in advanced Parkinson's disease patients treated with carbidopa-levodopa-entacapone
    Hsu, A.
    Khanna, S.
    Kell, S.
    Espay, A.
    Gil, R.
    Singer, C.
    Gupta, S.
    MOVEMENT DISORDERS, 2013, 28 : S149 - S149
  • [37] Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial
    Waters, Cheryl H.
    Nausieda, Paul
    Dzyak, Lyudmila
    Spiegel, Joerg
    Rudzinska, Monika
    Silver, Dee E.
    Tsurkalenko, Elena S.
    Kell, Sherron
    Hsu, Ann
    Khanna, Sarita
    Gupta, Suneel
    CNS DRUGS, 2015, 29 (04) : 341 - 350
  • [38] Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naive early Parkinson's disease (APEX-PD trial)
    Pahwa, R.
    Ellenbogen, A.
    Jankovic, J.
    Hauser, R.
    Fahn, S.
    MOVEMENT DISORDERS, 2011, 26 : S137 - S137
  • [39] Extended-release oral capsule of carbidopa-levodopa in Parkinson disease
    Margolesky, Jason
    Singer, Carlos
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 11 : 1 - 12
  • [40] HOW TO DOSE EXTENDED-RELEASE CARBIDOPA-LEVODOPA CAPSULES (IPX203) IN PARKINSON'S DISEASE PATIENTS: EXPERIENCE FROM THE PHASE 3 CLINICAL TRIAL
    Hauser, R. A.
    Banisadr, G.
    Fisher, S.
    Visser, H.
    D'Souza, R.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
12345